ArticleScientific reports2026
The association of a common HFE gene variant with stroke disability utilizing predictive machine learning and electronic health records.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Animal studies demonstrate that the H67D HFE mutation is neuroprotective against intracerebral hemorrhage (ICH), but whether the human analog, H63D HFE, confers a similar effect is unknown. We developed a machine learning algorithm to predict discharge Modified Rankin Score (mRS ≤ 2 functionally independent vs. ≥ 3 moderate-severe disability) from electronic health records (EHR) of stroke patients. This model was applied to large genetic databases to determine the association between the H63D mutation and predicted stroke disability. Four algorithms were trained on ICD-10 codes from 6,500 stroke patient records to predict dichotomized discharge mRS. The best model was applied to UK Biobank and AllofUs stroke cohorts, and the association of predicted mRS with H63D mutation was assessed by logistic regression. Although all models performed similarly, the gradient boosting model achieved the highest performance (AUROC 86.66; AUPRC 89.51). ICH patients without the H63D mutation had significantly higher odds of predicted disability (mRS ≥ 3) compared to carriers (OR 1.42, p = 0.044). No association was observed in other stroke types. Our study presents evidence that the commonly found H63D HFE mutation is associated with decreased ICH disability. These findings highlight a potential genetic mechanism that could guide future therapeutic strategies for ICH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.